{"disease":{"id":"egfr-positive-non-small-cell-lung-cancer","name":"egfr positive non small cell lung cancer"},"drugs":{"marketed":[{"drug_id":"dacomitinib-hydrate","indication_name":"EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"dacomitinib hydrate","generic_name":"dacomitinib-hydrate","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3","drug_class":"The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho","quality_score":null,"revenue":null,"mechanism":"The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho"},{"drug_id":"vizimpro","indication_name":"EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizimpro","generic_name":"Dacomitinib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3","drug_class":"Tyrosine kinase inhibitor (TKI); Pan-HER inhibitor","quality_score":75,"revenue":null,"mechanism":"Irreversible pan-HER kinase inhibitor targeting EGFR, HER2, HER4, and EGFR-activating mutations."},{"drug_id":"dacomitinib","indication_name":"EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizimpro","generic_name":"dacomitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Vizimpro works by blocking the EGFR tyrosine kinase, a protein that helps cancer cells grow and survive."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02296125","title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":674,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04105153","title":"Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Thoraxklinik-Heidelberg gGmbH","has_results":false},{"nct_id":"NCT07239102","title":"Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT02729298","title":"First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"Sumitomo Pharma America, Inc.","has_results":false},{"nct_id":"NCT04862780","title":"(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":177,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT05033691","title":"A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases","phase":"NA","overall_status":"RECRUITING","enrollment_count":162,"lead_sponsor_name":"Hadassah Medical Organization","has_results":false},{"nct_id":"NCT03239340","title":"A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06982924","title":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":136,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT03126799","title":"A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":128,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT05962021","title":"Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04027647","title":"Phase 2 Study of Dacomitinib in NSCLC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":118,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT02228369","title":"Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06631989","title":"A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Wayshine Biopharm, Inc.","has_results":false},{"nct_id":"NCT05338619","title":"A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":77,"lead_sponsor_name":"Sung Yong Lee","has_results":false},{"nct_id":"NCT04900935","title":"Patient-centered, Optimal Integration of Survivorship and Palliative Care","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03382795","title":"Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":63,"lead_sponsor_name":"Korea University Guro Hospital","has_results":false},{"nct_id":"NCT07322783","title":"Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Qingdao Central Hospital","has_results":false},{"nct_id":"NCT02932345","title":"Gefitinib Long-term Survivor Study","phase":"","overall_status":"TERMINATED","enrollment_count":59,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04643847","title":"A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":47,"lead_sponsor_name":"First People's Hospital of Hangzhou","has_results":false},{"nct_id":"NCT03319459","title":"FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT06208033","title":"SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT07298148","title":"Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05153408","title":"(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false}],"total":23},"guidelines":[],"source":"Drug Landscape verified database"}